Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706-based PRaG therapy plus thymalfasin in unresectable hepatocellular carcinoma (second-line)
ChiCTR2500106880Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500106880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106880.